Boston Scientific Corporation (BSX) : Argent Capital Management reduced its stake in Boston Scientific Corporation by 0.49% during the most recent quarter end. The investment management company now holds a total of 2,200,040 shares of Boston Scientific Corporation which is valued at $52,492,954 after selling 10,870 shares in Boston Scientific Corporation , the firm said in a disclosure report filed with the SEC on Aug 8, 2016.Boston Scientific Corporation makes up approximately 2.23% of Argent Capital Management’s portfolio.
Other Hedge Funds, Including , Moors Cabot boosted its stake in BSX in the latest quarter, The investment management firm added 1,250 additional shares and now holds a total of 42,125 shares of Boston Scientific Corporation which is valued at $1,005,103. Boston Scientific Corporation makes up approx 0.17% of Moors Cabot’s portfolio.Ngam Advisors boosted its stake in BSX in the latest quarter, The investment management firm added 11,136 additional shares and now holds a total of 57,514 shares of Boston Scientific Corporation which is valued at $1,371,134. Boston Scientific Corporation makes up approx 0.02% of Ngam Advisors’s portfolio. First National Bank Of Omaha added BSX to its portfolio by purchasing 223,979 company shares during the most recent quarter which is valued at $5,433,731. Boston Scientific Corporation makes up approx 0.41% of First National Bank Of Omaha’s portfolio.Beech Hill Advisors reduced its stake in BSX by selling 3,500 shares or 16.57% in the most recent quarter. The Hedge Fund company now holds 17,617 shares of BSX which is valued at $427,388. Boston Scientific Corporation makes up approx 0.28% of Beech Hill Advisors’s portfolio.
Boston Scientific Corporation opened for trading at $23.98 and hit $24.08 on the upside on Monday, eventually ending the session at $23.97, with a gain of 0.33% or 0.08 points. The heightened volatility saw the trading volume jump to 50,15,963 shares. Company has a market cap of $32,617 M.
On the company’s financial health, Boston Scientific Corporation reported $0.27 EPS for the quarter, based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus estimate of $0.27. The company had revenue of $2126.00 million for the quarter, compared to analysts expectations of $2044.88 million. The company’s revenue was up 15.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.22 EPS.
Many Wall Street Analysts have commented on Boston Scientific Corporation. Company shares were Reiterated by Wedbush on Jul 29, 2016 to “Neutral”, Firm has raised the Price Target to $ 25 from a previous price target of $23 .Company shares were Reiterated by Needham on Jul 29, 2016 to “Buy”, Firm has raised the Price Target to $ 28 from a previous price target of $26 .Company shares were Reiterated by The Benchmark Company on Jul 28, 2016 to “Buy”, Firm has raised the Price Target to $ 31 from a previous price target of $25 .
Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Womens Health and Neuromodulation.